Erasca (ERAS) Enterprise Value (2020 - 2026)
Erasca's (ERAS) quarterly Enterprise Value came in at -$243.8 million in Q1 2026, up 19.96% YoY from -$203.2 million in Q1 2025, and up 11.7% on a QoQ basis from -$276.1 million in Q4 2025.
Erasca (ERAS) Enterprise Value (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Enterprise Value data on file, last reported at -$243.8 million in Q1 2026.
- Quarterly Enterprise Value rose 19.96% year-over-year to -$243.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$243.8 million (up 19.96% YoY) and the FY2025 annual result came in at -$276.1 million, up 7.45% from the prior year.
- Enterprise Value grew to -$243.8 million in Q1 2026, from -$276.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$243.8 million in Q1 2026 to a low of -$435.6 million in Q4 2022.
- A 5-year average of -$330.9 million and a median of -$312.3 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value sank 130.92% — and 2023, when it advanced 28.3%.
- Tracing ERAS's Enterprise Value over 5 years: stood at -$435.6 million in 2022, then grew by 28.3% to -$312.3 million in 2023, then advanced by 4.5% to -$298.3 million in 2024, then grew by 7.45% to -$276.1 million in 2025, then climbed by 11.7% to -$243.8 million in 2026.
- The last three Enterprise Value figures came in at -$243.8 million (Q1 2026), -$276.1 million (Q4 2025), and -$288.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | -268.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -268.74 Mn |
| Mar 31, 2026 | -243.79 Mn |
| Dec 31, 2025 | -276.08 Mn |
| Sep 30, 2025 | -288.40 Mn |
| Jun 30, 2025 | -300.66 Mn |
| Mar 31, 2025 | -304.59 Mn |
| Dec 31, 2024 | -298.31 Mn |
| Sep 30, 2024 | -318.91 Mn |
| Jun 30, 2024 | -408.41 Mn |
| Mar 31, 2024 | -393.76 Mn |
| Dec 31, 2023 | -312.35 Mn |
| Sep 30, 2023 | -296.67 Mn |
| Jun 30, 2023 | -317.25 Mn |
| Mar 31, 2023 | -389.74 Mn |
| Dec 31, 2022 | -435.62 Mn |
| Sep 30, 2022 | -355.93 Mn |
| Jun 30, 2022 | -292.73 Mn |
| Mar 31, 2022 | -392.53 Mn |
| Dec 31, 2021 | -414.48 Mn |
| Sep 30, 2021 | -486.65 Mn |